Resilience Is the New Capacity: Building Manufacturing Advantage Through Strategic CDMO Partnerships
Day 2 Next-Gen Bio Stage
07/10/2026 14:15 - 14:40pm
Contributors
Fenil Patel : External Tech Transfer Director - Rezon Bio
As biologics programs advance toward commercialization, success increasingly depends on the ability to combine quality, price competitiveness, technological fit, and product-oriented partnerships with regulatory alignment. Manufacturing advantage is no longer defined by capacity alone.
The companies best positioned for commercial success are those that combine quality and reliability (Baseline), competitive and scalable operations (Differentiator), technological fit and regulatory execution scientific excellence (Accelerant), and product-oriented partnerships (Confidence) to create resilient manufacturing networks capable of supporting the full product lifecycle.
This session explores how biopharma and biotech companies can create manufacturing advantage through the right CDMO partnerships and resilient supply strategies, including dual-site and network sourcing, to mitigate risk, maintain supply continuity and accelerate the path to commercialization.